Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Relypsa Files For Stock Offering

by Marc S. Reisch
October 7, 2013 | A version of this story appeared in Volume 91, Issue 40

Pharmaceutical maker Relypsa has filed paperwork with the Securities & Exchange Commission for an initial public offering of $127 million in stock. The firm’s lead drug, patiromer, is a potassium-binding polymer now in Phase III clinical trials for the treatment of high levels of potassium in the blood, a condition known as hyperkalemia. Patients with chronic kidney disease are often unable to excrete potassium and develop hyperkalemia, which can lead to cardiac arrhythmias and sudden death. Relypsa says funds raised in the stock offering will go to manufacturing and commercializing patiromer following FDA approval.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.